Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 14/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.80 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.64 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733725 | 0.91 | AURKA (0.68) | AURKACYP3A4CYP2D6CYP2C9AURKB | |
| SCHEMBL207884 | 0.91 | AURKA (0.80) | AURKACYP3A4CYP2D6CYP2C9AURKB | |
| SCHEMBL14495789 | 0.91 | AURKA (0.65) | AURKACYP3A4CYP2D6CYP2C9AURKB | |
| SCHEMBL211566 | 0.90 | AURKA (0.66) | AURKACYP3A4CYP2D6CYP2C9AURKB | |
| SCHEMBL210791 | 0.89 | AURKA (0.80) | AURKACYP3A4CYP2D6CYP2C9AURKB | |
| SCHEMBL207556 | 0.89 | AURKA (0.80) | AURKACYP3A4CYP2D6CYP2C9AURKB | |
| SCHEMBL29400762 | 0.89 | AURKA (1.00) | AURKACYP3A4CYP2D6CYP2C9AURKB | |
| SCHEMBL209775 | 0.89 | AURKA (0.63) | AURKACYP3A4CYP2D6CYP2C9AURKB | |
| SCHEMBL210005 | 0.88 | AURKA (0.65) | AURKACYP3A4CYP2D6CYP2C9AURKB | |
| SCHEMBL208782 | 0.87 | AURKA (0.67) | AURKACYP3A4CYP2D6CYP2C9AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | disclosed |
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2014-02-06 | — | — | US | disclosed |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2014-02-06 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | TFEB, SQSTM1, ULK1 | AURKA 1740/4885CYP3A4 4112/4885CYP2D6 4404/4885 |
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | AURKA 3/4885CYP3A4 439/4885CYP2D6 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.